Argenica Therapeutics was incorporated on 20 November 2019 as a proprietary Australian company to undertake the development and commercialisation of a novel therapeutic known as ARG-007 developed by world-leading researchers at the University of Western Australia (UWA) and the Perron Institute for Neurological and Translational Science (Perron Institute). The therapeutic, which is based on arginine rich peptides, has proven neuroprotective properties and therefore can offer protection to the brain following stroke and other acute central nervous system injuries.
The Company’s current business is to develop and commercialise ARG-007. Argenica will initially focus on the use of ARG-007 in the treatment of stroke.
The Company has no subsidiaries.
It is anticipated that AGN will list on the ASX during June 2021.
Be the first to comment